T cell-depleted unrelated donor stem cell transplantation provides favorable disease-free survival for adults with hematologic malignancies

Biology of Blood and Marrow Transplantation

Volumn 17, Issue 9, 2011, Pages 1335-1342

  Jakubowski, Ann A ^a   Small, Trudy N ^a   Kernan, Nancy A ^a   Castro Malaspina, Hugo ^a   Collins, Nancy ^a   Koehne, Guenther ^a   Hsu, Katharine C ^a   Perales, Miguel A ^a   Papanicolaou, Genovefa ^a   van den Brink, Marcel R M ^a   O'Reilly, Richard J ^a   Young, James W ^a   Papadopoulos, Esperanza B ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Hematologic malignancies; Hematopoietic stem cell transplant; T cell depletion; Unrelated donor

Indexed keywords

FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; THIOTEPA; THYMOCYTE ANTIBODY;

ADULT; ARTICLE; CANCER RELAPSE; CD34 SELECTION; CLINICAL ARTICLE; DISEASE FREE SURVIVAL; DONOR; GRAFT FAILURE; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HLA MATCHING; HUMAN; INFECTION; PERIPHERAL BLOOD STEM CELL; PHASE 2 CLINICAL TRIAL; SHEEP ERYTHROCYTE; STEM CELL TRANSPLANTATION; T CELL DEPLETION; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; DISEASE-FREE SURVIVAL; FEMALE; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOCYTE DEPLETION; MALE; MIDDLE AGED; T-LYMPHOCYTES; TISSUE DONORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79960217520     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2011.01.005     Document Type: Article

References (45)

1. Young J., Papadopoulos E., Cunningham I., et al. T-cell-depleted allogeneic bone marrow transplantation in adults with acute nonlymphocytic leukemia in first remission. Blood 1992, 79:3380-3387.
2. Papadopoulos E., Carabasi M., Castro-Malaspina H., et al. T-cell-depleted allogeneic bone marrow transplantation as postremission therapy for acute myelogenous leukemia: freedom from relapse in the absence of graft-versus-host disease. Blood 1998, 91:1083-1090.
3. Alyea E.P., Weller E., Fisher D.C., et al. Comparable outcome with T-cell depleted unrelated donor versus related donor allogeneic bone marrow transplantation. Biol Blood Marrow Transplant 2002, 8:601-607.
4. Novitzky N., Thomas V., Hale G., Waldmann H. Myeloablative conditioning is well tolerated by older patients receiving T-cell-depleted grafts. Bone Marrow Transplant 2005, 36:675-682.
5. Jakubowski A.A., Small T.N., Young J.W., et al. T cell depleted stem-cell transplantation for adults with hematologic malignancies: sustained engraftment of HLA-matched related donor grafts without the use of antithymocyte globulin. Blood 2007, 110:4552-4559.
6. Le R.Q., Bevans M., Savani B.N., et al. Favorable outcomes in patients surviving 5 or more years after allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Biol Blood Marrow Transplant 2010, 16:1162-1170.
7. Wagner J.E., Thompson J.S., Carter S.L., Kernan N.A. Effect of graft-versus-host disease prophylaxis on 3-year disease-free survival in recipients of unrelated donor bone marrow (T-cell Depletion trial): a multi-centre, randomised phase II-III trial. Lancet 2005, 366:733-741. for the Unrelated Donor Marrow Transplantation Trial.
8. von dem Borne P.A., Beaumont F., Starrenburg C.W., et al. Outcomes after myeloablative unrelated donor stem cell transplantation using both in vitro and in vivo T-cell depletion with alemtuzumab. Haematologica 2006, 91:1559-1562.
9. Kernan N., Bordignon C., Heller G., et al. Graft failure after T-cell-depleted human leukocyte antigen identical marrow transplants for leukemia: I. Analysis of risk factors and results of secondary transplants. Blood 1989, 74:2227-2236.
10. Aversa F., Terenzi A., Carotti A., et al. Improved outcome with T-cell-depleted bone marrow transplantation for acute leukemia. J Clin Oncol 1999, 17:1545.
11. Small T.N., Avigan D., Dupont B., et al. Immune reconstitution following T-cell depleted bone marrow transplantation: effect of age and posttransplant graft rejection prophylaxis. Biol Blood Marrow Transplant 1997, 3:65-75.
12. Byrd J.C., Mrozek K., Dodge R.K., et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from cancer and leukemia group B (CALGB 8461). Blood 2002, 100:4325-4336.
13. Collins N.H., Fernandez J.M., Bleau S., et al. Comparison of bone marrow and G-CSF mobilized peripheral blood progenitor cells from single normal donors before and after T cell depletion. Cytotherapy 1999, 1.
14. Collins N.H., Bleau S.A., Kernan N.A., O'Reilly R.J. T cell depletion of bone marrow by treatment with soybean agglutinin and sheep red blood cell rosetting. Bone Marrow and Stem Cell Processing: A Manual of Current Techniques 1991, 171-180. F.A. Davis, Philadelphia, PA. H.J. Areman, H.J. Deeg, R.A. Sacher (Eds.).
15. Rowlings P.A., Przepiorka D., Klein J.P., et al. IBMTR severity index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade. Br J Haematol 1997, 97:855-864.
16. Sullivan K., Shulman H., Storb R., et al. Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression. Blood 1981, 57:267-276.
17. Niesters H.G.M., van Esser J., Fries E., Wolthers K.C., Cornelissen J., Osterhaus A.D.M.E. Development of a real-time quantitative assay for detection of Epstein-Barr virus. J Clin Microbiol 2000, 38:712-715.
18. Small T.N., Papadopoulos E.B., Boulad F., et al. Comparison of immune reconstitution after unrelated and related T-cell-depleted bone marrow transplantation: effect of patient age and donor leukocyte infusions. Blood 1999, 93:467-480.
19. Kalbfleisch J.D., Prentice R.L. The Statisical Analysis of Failure Time Data 1980, Wiley, New York, NY.
20. Copelan E., Casper J.T., Carter S.L., et al. A scheme for defining cause of death and its application in the T cell depletion trial. Biol Blood Marrow Transplant 2007, 13:1469-1476.
21. Kernan N., Collins N., Juliano L., Cartagena T., Dupont B., O'Reilly R. Clonable T lymphocytes in T cell-depleted bone marrow transplants correlate with development of graft-v-host disease. Blood 1986, 68:770-773.
22. Savani B.N., Mielke S.S., Rezvani K.K., et al. Absolute lymphocyte count on day 30 is a surrogate for robust hematopoietic recovery and strongly predicts outcome after T cell-depleted allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2007, 13:1216-1223.
23. Soiffer R.R.J., Weller E.E., Alyea E.E.P., et al. CD6+ donor marrow T-cell depletion as the sole form of graft-versus-host disease prophylaxis in patients undergoing allogeneic bone marrow transplant from unrelated donors. J Clin Oncol 2001, 19:1152-1159.
24. Soiffer R.J., Alyea E.P., Hochberg E., et al. Randomized trial of CD8+ T-cell depletion in the prevention of graft-versus-host disease associated with donor lymphocyte infusion. Biol Blood Marrow Transplant 2002, 8:625-632.
25. Kalaycio M., Rybicki L., Pohlman B., et al. CD8+ T-cell-depleted, matched unrelated donor, allogeneic bone marrow transplantation for advanced AML using busulfan-based preparative regimens. Bone Marrow Transplant 2005, 35:247-252.
26. Patel B., Kirkland K.E., Szydlo R., et al. Favorable outcomes with alemtuzumab-conditioned unrelated donor stem cell transplantation in adults with high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in first complete remission. Haematologica 2009, 94:1399-1406.
27. Casper J., Camitta B., Truitt R., et al. Unrelated bone marrow donor transplants for children with leukemia or myelodysplasia. Blood 1995, 85:2354-2363.
28. Chown S.R., Marks D.I., Cornish J.M., et al. Unrelated donor bone marrow transplantation in children and young adults with acute myeloid leukaemia in remission. Br J Haematol 1997, 99:36-40.
29. Hessner M.J., Endean D.J., Casper J.T., et al. Use of unrelated marrow grafts compensates for reduced graft-versus-leukemia reactivity after T-cell-depleted allogeneic marrow transplantation for chronic myelogenous leukemia. Blood 1995, 86:3987-3996.
30. Drobyski W.R., Hessner M.J., Klein J.P., Kabler-Babbitt C., Vesole D.H., Keever-Taylor C.A. T-cell depletion plus salvage immunotherapy with donor leukocyte infusions as a strategy to treat chronic-phase chronic myelogenous leukemia patients undergoing HLA-identical sibling marrow transplantation. Blood 1999, 94:434-441.
31. Sehn L.H., Alyea E.P., Weller E., et al. Comparative outcomes of T-cell-depleted and non-T-cell-depleted allogeneic bone marrow transplantation for chronic myelogenous leukemia: impact of donor lymphocyte infusion. J Clin Oncol 1999, 17:561-568.
32. Meijer E., Bloem A.C., Dekker A.W., Verdonck L.F. Effect of antithymocyte globulin on quantitative immune recovery and graft-versus-host disease after partially T-cell-depleted bone marrow transplantation: a comparison between recipients of matched related and matched unrelated donor grafts. Transplantation 2003, 75:1910-1913.
33. Wagner J.E., Thompson J.S., Carter S.L., Kernan N.A. Effect of graft-versus-host disease prophylaxis on 3-year disease-free survival in recipients of unrelated donor bone marrow (T-cell depletion trial): a multi-centre, randomised phase II-III trial. Lancet 2005, 366:733-741.
34. Baron F., Maris M.B., Storer B.E., et al. High doses of transplanted CD34+ cells are associated with rapid T-cell engraftment and lessened risk of graft rejection, but not more graft-versus-host disease after nonmyeloablative conditioning and unrelated hematopoietic cell transplantation. Leukemia 2005, 19:822-828.
35. Zaucha J.M., Gooley T., Bensinger W.I., et al. CD34 cell dose in granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell grafts affects engraftment kinetics and development of extensive chronic graft-versus-host disease after human leukocyte antigen-identical sibling transplantation. Blood 2001, 98:3221-3227.
36. Reisner Y., Martelli M.F. Transplantation tolerance induced by "mega dose" CD34+ cell transplants. Exp Hematol 2000, 28:119-127.
37. Yakoub-Agha I., Mesnil F., Kuentz M., et al. Allogeneic marrow stem cell transplantation from human leukocyte antigen-identical siblings versus human leukocyte antigen-allelic-matched unrelated donors (10/10) in patients with standard-risk hematologic malignancy: a prospective study from the French Society of Bone Marrow Transplantation and Cell Therapy. J Clin Oncol 2006, 24:5695-5702.
38. Devine S.M., Soiffer R.J., Pasquini M.C., et al. HLA-identical sibling-matched, CD34+ selected, T cell depleted peripheral blood stem cells following myeloablative conditioning for first or second remission acute myeloid leukemia (AML): results of blood and marrow transplant clinical trials network (BMT CTN) protocol 0303. Blood 2009, 114:655a.
39. Hsu K.C., Keever-Taylor C.A., Wilton A., et al. Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes. Blood 2005, 105:4878-4884.
40. Bordignon C., Keever C., Small T., et al. Graft failure after T-cell-depleted human leukocyte antigen identical marrow transplants for leukemia: II. In vitro analyses of host effector mechanisms. Blood 1989, 74:2237-2243.
41. Aversa F., Tabilio A., Velardi A., et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med 1998, 339:1186-1193.
42. Keever-Taylor C.A., Wagner J.E., Kernan N.A., et al. Comparison of immune recovery in recipients of unmanipulated vs T-cell-depleted grafts from unrelated donors in a multicenter randomized phase II-III trial (T-cell depletion trial). Bone Marrow Transplant 2010, 45:587-589.
43. Wagner J, C A, Kollman C, et al. Unrelated donor bone marrow transplantation in 5075 patients with malignant and non-malignant disease: effect of graft-versus-host disease prophylaxis on treatment outcome. Blood. 1998;92:686a.
44. van Burik J.-A.H., Carter S.L., Freifeld A.G., et al. Higher risk of cytomegalovirus and aspergillus infections in recipients of T cell-depleted unrelated bone marrow: analysis of infectious complications in patients treated with T cell depletion versus immunosuppressive therapy to prevent graft-versus-host disease. Biol Blood Marrow Transplant 2007, 13:1487-1498.
45. Chatchada K., Gene O.N., Pintip C., et al. Twenty years of unrelated donor hematopoietic cell transplantation for adult recipients facilitated by the national marrow donor program. Biol Blood Marrow Transplant 2008, 14:8-15.